In today’s rapidly advancing pharmaceutical landscape, evidence generation plays a crucial role in shaping innovation and policy. Within this context, Systematic Literature Reviews (SLRs) and Targeted Literature Reviews (TLRs) have become essential mechanisms for generating reliable insights. SLRs serve as the benchmark for rigorous evidence synthesis, offering a structured, transparent, and fully reproducible method for compiling clinical data. Because they typically follow established frameworks such as PRISMA or Cochrane guidelines, SLRs are widely relied upon for regulatory filings, health technology assessments (HTAs), and strategic clinical development decisions.
TLRs, on the other hand, provide a more streamlined and flexible approach. They are designed to quickly address focused research needs—whether mapping treatment landscapes, understanding epidemiological trends, or informing early-stage development questions.
Together, SLRs and TLRs create a robust, complementary evidence infrastructure that enables pharmaceutical teams to make timely, data-driven decisions throughout the entire product lifecycle—from early research to market launch and beyond.
Read more in our latest Point of View here : Systemic Literature Review: Accelerating Evidence-Based Decisions in Pharma
